{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T09:26:49Z","timestamp":1758446809766,"version":"3.44.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1016\/j.metabol.2007.01.004","type":"journal-article","created":{"date-parts":[[2007,4,19]],"date-time":"2007-04-19T07:28:22Z","timestamp":1176967702000},"page":"699-707","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Serum osteoprotegerin and soluble receptor activator of nuclear factor \u03baB ligand levels in patients with a history of differentiated thyroid carcinoma: a case-controlled cohort study"],"prefix":"10.1016","volume":"56","author":[{"given":"Massimo","family":"Giusti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Cecoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Fazzuoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzina","family":"De Franchis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrica","family":"Ceresola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Ferone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Mussap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Minuto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2007.01.004_bib1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.metabol.2007.01.004_bib2","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1210\/endo.139.3.5837","article-title":"Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin: a mechanism by which OPG\/OCIF inhibits osteoclastogenesis in vitro","volume":"139","author":"Yasuda","year":"1998","journal-title":"Endocrinology"},{"key":"10.1016\/j.metabol.2007.01.004_bib3","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1084\/jem.186.12.2075","article-title":"TRANCE (tumor necrosis factor [TNF]\u2013related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell\u2013specific survival factor","volume":"186","author":"Wong","year":"1997","journal-title":"J Exp Med"},{"key":"10.1016\/j.metabol.2007.01.004_bib4","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.metabol.2007.01.004_bib5","doi-asserted-by":"crossref","first-page":"6113","DOI":"10.4049\/jimmunol.161.11.6113","article-title":"OPG\/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40","volume":"161","author":"Yun","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.metabol.2007.01.004_bib6","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/jcb.10242","article-title":"Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland","volume":"86","author":"Hofbauer","year":"2002","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.metabol.2007.01.004_bib7","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","article-title":"Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to TRANCE\/RANKL","volume":"95","author":"Yasuda","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.metabol.2007.01.004_bib8","doi-asserted-by":"crossref","first-page":"14363","DOI":"10.1074\/jbc.273.23.14363","article-title":"Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL","volume":"273","author":"Emery","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2007.01.004_bib9","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1101\/gad.12.9.1260","article-title":"Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification","volume":"12","author":"Bucay","year":"1998","journal-title":"Genes Dev"},{"key":"10.1016\/j.metabol.2007.01.004_bib10","doi-asserted-by":"crossref","first-page":"6323","DOI":"10.1210\/jc.2005-0794","article-title":"Review: circulating osteoprotegerin and receptor activator of nuclear factor kB ligand: clinical utility in metabolic bone disease assessment","volume":"90","author":"Rogers","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2007.01.004_bib11","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1083\/jcb.145.3.527","article-title":"The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts","volume":"145","author":"Burgess","year":"1999","journal-title":"J Cell Biol"},{"key":"10.1016\/j.metabol.2007.01.004_bib12","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S8756-3282(00)00453-1","article-title":"The effect of macrophage-colony stimulating factor and other humoral factors (interleukin-1, -3, -6 and -11, tumor necrosis factor-alpha, and granulocyte macrophage-colony stimulating factor) on human osteoclast formation from circulating cells","volume":"28","author":"Fujikawa","year":"2001","journal-title":"Bone"},{"key":"10.1016\/j.metabol.2007.01.004_bib13","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1006\/bbrc.1998.9788","article-title":"RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis","volume":"253","author":"Nakagawa","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.metabol.2007.01.004_bib14","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1073\/pnas.96.7.3540","article-title":"Tumor necrosis factor receptor family member RANK mediates the osteoclast differentiation and activation induced by osteoprotegerin ligand","volume":"96","author":"Hsu","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.metabol.2007.01.004_bib15","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/16852","article-title":"OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis","volume":"397","author":"Kong","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.metabol.2007.01.004_bib16","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1161\/01.CIR.0000127957.43874.BB","article-title":"Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease","volume":"109","author":"Kiechl","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2007.01.004_bib17","first-page":"2355","article-title":"The role of osteoprotegerin and receptor activator of nuclear factor-kB ligand in the pathogenesis and treatment of metabolic bone diseases","volume":"85","author":"Hofbauer","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2007.01.004_bib18","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/1097-0142(20010801)92:3<460::AID-CNCR1344>3.0.CO;2-D","article-title":"Receptor activator of nuclear factor-kB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases","volume":"92","author":"Hofbauer","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.metabol.2007.01.004_bib19","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0167-5699(00)01718-7","article-title":"Osteoprotegerin ligand: a regulator of immune responses and bone physiology","volume":"21","author":"Kong","year":"2000","journal-title":"Immunol Today"},{"key":"10.1016\/j.metabol.2007.01.004_bib20","first-page":"518","article-title":"The effect of a single dose of osteoprotegerin in postmenopausal women","volume":"14","author":"Bekker","year":"2001","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2007.01.004_bib21","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/BF03345061","article-title":"Bone turnover in hyperthyroidism before and after thyrostatic management","volume":"23","author":"Isaia","year":"2000","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.metabol.2007.01.004_bib22","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.bone.2004.04.021","article-title":"High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment","volume":"35","author":"Amato","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.metabol.2007.01.004_bib23","doi-asserted-by":"crossref","first-page":"5765","DOI":"10.1210\/jc.2005-0562","article-title":"Changes in plasma concentrations of osteoprotegerin before and after levothyroxine replacement therapy in hypothyroid patients","volume":"90","author":"Guang-da","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2007.01.004_bib24","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1530\/eje.1.01870","article-title":"Increased levels of serum osteoprotegerin in hypothyroid patients and its normalization with restoration of normal thyroid function","volume":"152","author":"Nagasaki","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.metabol.2007.01.004_bib25","doi-asserted-by":"crossref","first-page":"561","DOI":"10.7326\/0003-4819-134-7-200104030-00009","article-title":"Risk for fracture in women with low serum levels of thyroid-stimulating hormone","volume":"134","author":"Bauer","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.metabol.2007.01.004_bib26","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1677\/erc.1.01072","article-title":"Lack of deleterious effect on bone mineral density of long-term thyroxine suppressive therapy for differentiated thyroid carcinoma","volume":"12","author":"Reverter","year":"2005","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.metabol.2007.01.004_bib27","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.arcmed.2005.09.009","article-title":"Relationship between subclinical thyroid dysfunction and femoral neck bone mineral density in women","volume":"37","author":"Lee","year":"2006","journal-title":"Arch Med Res"},{"key":"10.1016\/j.metabol.2007.01.004_bib28","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s001980050069","article-title":"Bone changes in pre- and postmenopausal women with thyroid cancer on levothyroxine: evolution of axial and appendicular bone mass","volume":"8","author":"Jodar","year":"1998","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.metabol.2007.01.004_bib29","first-page":"3","article-title":"Bone loss in premenopausal women on long-term suppressive therapy with thyroid hormone","volume":"6","author":"Sijanovic","year":"2001","journal-title":"Medscape Womens Health"},{"key":"10.1016\/j.metabol.2007.01.004_bib30","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1185\/030079906X115612","article-title":"Changes of bone mineral density in pre-menopausal women with differentiated thyroid cancer receiving l-thyroxine suppressive therapy","volume":"22","author":"Mazokopakis","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.metabol.2007.01.004_bib31","first-page":"442","article-title":"Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma","volume":"103","author":"Chen","year":"2004","journal-title":"J Formos Med Assoc"},{"issue":"Suppl 3","key":"10.1016\/j.metabol.2007.01.004_bib32","first-page":"S71","article-title":"The comparative study of bone mineral density between premenopausal women receiving long-term suppressive doses of levothyroxine for well-differentiated thyroid cancer with healthy premenopausal women","volume":"88","author":"Sajjinaanont","year":"2005","journal-title":"J Med Assoc Thai"},{"key":"10.1016\/j.metabol.2007.01.004_bib33","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1530\/eje.1.01933","article-title":"Hip bone mineral density, bone turnover and risk of fracture in patients on long-term suppressive l-thyroxine therapy for differentiated thyroid carcinoma","volume":"153","author":"Heijckmann","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.metabol.2007.01.004_bib34","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s00223-003-0033-5","article-title":"Triiodothyronine (T3) and 1,25-dihydroxyvitamin D3 (1,25D3) inversely regulate OPG gene expression in dependence of the osteoblastic phenotype","volume":"74","author":"Varga","year":"2004","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.metabol.2007.01.004_bib35","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1359\/jbmr.1999.14.4.518","article-title":"Immunological characterization of circulating osteoprotegerin\/osteoclastogenesis inhibitory factor. Increased serum concentrations in postmenopausal women with osteoporosis","volume":"14","author":"Yano","year":"1999","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2007.01.004_bib36","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1530\/eje.0.1450685","article-title":"Increased serum oteoprotegerin in disorders characterized by persistent immune activation of glucocorticoid excess\u2014possible role in bone homeostasis","volume":"145","author":"Ueland","year":"2001","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.metabol.2007.01.004_bib37","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/00002281-200307000-00013","article-title":"Mechanism of glucocorticoid-induced osteoporosis","volume":"15","author":"Canalis","year":"2003","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.metabol.2007.01.004_bib38","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1046\/j.1365-2265.1999.00626.x","article-title":"Bone turnover and cortical bone mineral density in the distal radius in patients with hyperthyroidism being treated with antithyroid drugs for various periods of time","volume":"50","author":"Olkawa","year":"1999","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.metabol.2007.01.004_bib39","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1046\/j.1365-2265.2002.01578.x","article-title":"Bone remodelling markers and serum cytokines in patients with hyperthyroidism","volume":"57","author":"Akalin","year":"2002","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.metabol.2007.01.004_bib40","first-page":"435","article-title":"Serum cytokines in thyrotoxicosis","volume":"84","author":"Siddiqi","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2007.01.004_bib41","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S8756-3282(03)00090-5","article-title":"Austrian Group on Normative Values of Bone Metabolism. Serum levels of osteoprotegerin increase with age in healthy adult population","volume":"32","author":"Kudlacek","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.metabol.2007.01.004_bib42","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00198-004-1699-x","article-title":"Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover","volume":"16","author":"Indridason","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.metabol.2007.01.004_bib43","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1359\/JBMR.041126","article-title":"Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin in postmenopausal women monitored for differentiated thyroid carcinoma","volume":"20","author":"Mazziotti","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2007.01.004_bib44","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/BF03349174","article-title":"Acute changes in clinical parameters and thyroid function peripheral markers following L-T4 withdrawal in patients totally thyroidectomized for thyroid cancer","volume":"29","author":"Regalbuto","year":"2006","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.metabol.2007.01.004_bib45","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1006\/bbrc.1998.9723","article-title":"Transforming growth factor-beta 1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic\/stromal cells and inhibits the survival of murine osteoclast-like cells","volume":"252","author":"Muratami","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.metabol.2007.01.004_bib46","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1210\/endo.142.6.8220","article-title":"17Beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha","volume":"142","author":"Saika","year":"2001","journal-title":"Endocrinology"},{"key":"10.1016\/j.metabol.2007.01.004_bib47","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1210\/endo.140.8.6887","article-title":"Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cells formation","volume":"140","author":"Lee","year":"1999","journal-title":"Endocrinology"},{"key":"10.1016\/j.metabol.2007.01.004_bib48","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.1210\/endo.140.10.7034","article-title":"Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis","volume":"140","author":"Hofbauer","year":"1999","journal-title":"Endocrinology"},{"key":"10.1016\/j.metabol.2007.01.004_bib49","first-page":"3162","article-title":"Osteoprotegerin serum levels in men: correlation with age, estrogen and testosterone status","volume":"86","author":"Szulc","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2007.01.004_bib50","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.1210\/jc.2002-020396","article-title":"Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women","volume":"87","author":"Rogers","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2007.01.004_bib51","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/jcb.10567","article-title":"Vitamin D3 supports osteoclastogenesis via functional vitamin D response element of human RANKL gene promoter","volume":"89","author":"Kitazawa","year":"2003","journal-title":"J Cell Biochem"},{"issue":"Suppl 10","key":"10.1016\/j.metabol.2007.01.004_bib52","first-page":"14","article-title":"Circulating osteoprotegerin and soluble RANKL: do they have a future in clinical practice?","volume":"28","author":"Dovio","year":"2005","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.metabol.2007.01.004_bib53","first-page":"125","article-title":"Changes in parameters of bone and mineral metabolism during therapy for hyperthyroidism","volume":"57","author":"Pantazi","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2007.01.004_bib54","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0092-8674(03)00771-2","article-title":"TSH is a negative regulator of skeletal remodelling","volume":"115","author":"Abe","year":"2003","journal-title":"Cell"},{"issue":"Suppl 4","key":"10.1016\/j.metabol.2007.01.004_bib55","first-page":"25","article-title":"Recombinant human TSH does not acutely change osteoprotegerin and receptor activator of nuclear factor ligand in differentiated thyroid carcinoma","volume":"29","author":"Cecoli","year":"2006","journal-title":"J Endocrinol Invest"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049507000443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049507000443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T03:22:23Z","timestamp":1758424943000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049507000443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["S0026049507000443"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2007.01.004","relation":{},"ISSN":["0026-0495"],"issn-type":[{"type":"print","value":"0026-0495"}],"subject":[],"published":{"date-parts":[[2007,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum osteoprotegerin and soluble receptor activator of nuclear factor \u03baB ligand levels in patients with a history of differentiated thyroid carcinoma: a case-controlled cohort study","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2007.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}